At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
We are a global frontrunner in making oral vaccines a reality. Weâve created a p...
We are a global frontrunner in making oral vacc...
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
Global Cancer Technology (GCT) is an emerging medical technology company with nu...
Global Cancer Technology (GCT) is an emerging...
We are a profitable and growing company focused on the acquisition, development an...
We are a profitable and growing company focused...
Join the National Investor Network and get the latest information with your interests in mind.